Straits Times Index
3,346.49 +16.48 (+0.49%) Nikkei
38,895.14 +404.97 (+1.05%) Hang Seng
18,503.79 +78.83 (+0.43%) FTSE 100
8,246.95 +14.91 (+0.18%) Bitcoin USD
71,154.04 +89.87 (+0.13%) CMC Crypto 200
1,526.14 +52.40 (+3.56%)
ATOS Jul 2024 2.000 call
| Previous close | 0.1000 |
| Open | 0.0700 |
| Bid | 0.0500 |
| Ask | 0.1000 |
| Strike | 2.00 |
| Expiry date | 2024-07-19 |
| Day's range | 0.0700 - 0.0700 |
| Contract range | N/A |
| Volume | |
| Open interest | 5.43k |
GlobeNewswireAtossa to Present at the Sidoti Small-Cap Investor Conference
SEATTLE, June 05, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced that the Company will present at the Sidoti Small-Cap Investor Conference being held June 12-13, 2024. The presentation by Steven Quay, M.D., Ph.D., Atossa’s President and Chief Executive Officer, will take place on Thursday, June 13 at 9:15 am eastern time. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unm
- GlobeNewswire
Atossa Therapeutics Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment Model
SEATTLE, May 28, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced support for a new Phase 2 study designed to validate an innovative, artificial intelligence driven, breast cancer risk assessment model. The SMART (Stockholm MAmmography Risk stratified Trial) study will test an individualized, imaging-based screening model designed to identify women with the highest risk of developing breast cancer in the next two years. If the model i
ZacksAtossa Genetics Inc. (ATOS) is a Great Momentum Stock: Should You Buy?
Does Atossa Genetics Inc. (ATOS) have what it takes to be a top stock pick for momentum investors? Let's find out.
